Thursday, January 13, 2022

Ocugen (OCGN)
New Study Shows Covaxin Neutralizes Omicron and Other Variants

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Covaxin Shows Efficacy Against Variants.  Ocugen announced that a new study at Emory University has shown that booster doses of Covaxin, its COVID-19 vaccine, produce effective levels of neutralizing antibodies against both the Omicron and Delta variants. We see this as consistent with previous variant tests, and highly comparable to the mRNA vaccines from Pfizer and Moderna.


Neutralizing Antibodies Were Found In 90% and 100% Of Patients Tested.  The study tested patients who received two initial doses of Covaxin followed by a booster six months later. Blood samples collected 28 days after the booster showed neutralizing antibodies against the Omicron variant in over 90% and against the Delta variant in 100% of the patients. This is consistent with previous tests showing …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.